home / stock / artl / artl news

ARTL News and Press, Artelo Biosciences Inc. From 08/10/23

Stock Information
Company Name: Artelo Biosciences Inc.
Stock Symbol: ARTL
Market: OTC
Website: artelobio.com
Menu
ARTL ARTL Quote ARTL Short ARTL News ARTL Articles ARTL Message Board
Get ARTL Alerts

News, Short Squeeze, Breakout and More Instantly...
ARTL - Artelo Biosciences Q2 GAAP EPS of -$0.56

2023-08-10 10:44:02 ET Artelo Biosciences press release ( NASDAQ: ARTL ): Q2 GAAP EPS of -$0.56. As of June 30, 2023, the company had approximately $14.0 million in cash and investments, compared to $17.5 million as of December 31, 2022. For further details see: ...
ARTL - Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported f...

ARTL - Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

SOLANA BEACH, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announ...

ARTL - Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11

SOLANA BEACH, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announ...
ARTL - Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium

SOLANA BEACH, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological cond...

ARTL - Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies for Chemotherapy-Induced Neuropathy and Diabetic Neuropathy ART26.12 targeting global neuropathic pain market valued at $7.6 billion in 2023 Anticipates FDA pre-IND meeting m...

ARTL - Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium

ART12.11, a novel and patented cocrystal of CBD reverses the impact of chronic stress on outcomes of anxiety, depression, sociability and cognition ART12.11 aims to address unmet needs within the global anxiety and depression market estimated to be in excess of $11 billion SOLANA...
ARTL - Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

SOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, t...

ARTL - Artelo Biosciences GAAP EPS of -$0.76

2023-05-11 09:40:34 ET Artelo Biosciences press release ( NASDAQ: ARTL ): Q1 GAAP EPS of -$0.76. As of March 31, 2023, the Company had approximately $15.5 million in cash and investments, compared to $17.5 million as of December 31, 2022. For further details see: ...

ARTL - Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today r...
Previous 10 Next 10